(+/-)-Hermitamide B | 907998-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (+/-)-Hermitamide B
• 英文别名: 2-(1H-indol-3-yl)-ethyl (4E)-methoxytetradecenamide；(rac)-hermitamide B；Rac-Hermitamide B；(E)-N-[2-(1H-indol-3-yl)ethyl]-7-methoxytetradec-4-enamide
• CAS: 907998-39-4
• 化学式: C₂₅H₃₈N₂O₂
• 分子量: 398.589
• InChiKey: OHYDYQKPXIXRBQ-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  29
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-hydroxy-5-methoxydodec-1-ene 在 1-羟基苯并三唑 、 丙酸 、 lithium hydroxide 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 34.5h， 生成 (+/-)-Hermitamide B
  参考文献：
  名称：

  Hermitamides A 和 B 作为人类电压门控钠通道阻滞剂的合成和评价

  摘要：

  Hermitamides A 和 B 是从巴布亚新几内亚海洋蓝藻Lyngbya majuscula 的集合中分离出来的脂肽。我们假设 Hermitamides 是人类电压门控钠通道 (hNa V ) 的配体，这是基于它们与牙买加酰胺的结构相似性。在此，我们描述了hermitamides A 和B 及其差向异构体的非外消旋全合成。我们报告了 Hermitamides比苯妥英（一种临床使用的钠通道阻滞剂）更有效地置换 10 μM 的[ 3 H]-BTX的能力。我们还在BTX 结合位点和电生理学中展示了 ( S )-hermitamide B的潜在结合模式，表明这些化合物是 hNav1.2 电压门控钠通道的有效阻滞剂。

  DOI：

  10.1016/j.bmc.2011.05.043

文献信息

• NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS
  申请人：Brown Milton L.

  公开号：US20110230442A1

  公开（公告）日：2011-09-22

  Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [ 3 H]-Batrachotoxin-B ([ 3 H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.

  本发明涉及分子及其合成，用于阻断门控离子通道，例如电压门控钠通道（VGSC）和前列腺电压钠通道（PVSC）。这些抑制剂具有卓越的阻断效力，例如在取代结合到VGSC的位点2的放射性配体[3H]-Batrachotoxin-B ([3H]-BTX-B)方面。本发明的分子包括一个基团，增加分子对前列腺癌细胞（PC）中蛋白质结合位点的结合亲和力，并且也是荧光的。在一种实施方式中，本发明的分子是一种抑制系统，可用于选择性地靶向过度丰富或过度活跃的VGSC，从而抑制疼痛、癫痫或前列腺癌的PC的增殖。荧光基团还有助于在体外和体内生物系统中筛选、跟踪和药效学研究药物。
• US8816095B2
  申请人：——

  公开号：US8816095B2

  公开（公告）日：2014-08-26
• [EN] NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS<br/>[FR] CANAUX SODIQUES, MALADIE, ET DOSAGES ET COMPOSITIONS APPARENTÉES
  申请人：UNIV GEORGETOWN

  公开号：WO2010019963A2

  公开（公告）日：2010-02-18

  Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target overabundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
• Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers
  作者：Eliseu O. De Oliveira、Kristin M. Graf、Manoj K. Patel、Aparna Baheti、Hye-Sik Kong、Linda H. MacArthur、Sivanesan Dakshanamurthy、Kan Wang、Milton L. Brown、Mikell Paige

  DOI：10.1016/j.bmc.2011.05.043

  日期：2011.7

  hermitamides are ligands for the human voltage-gated sodium channel (hNaV) based on their structural similarity to the jamaicamides. Herein, we describe the nonracemic total synthesis of hermitamides A and B and their epimers. We report the ability of the hermitamides to displace [3H]-BTX at 10 μM more potently than phenytoin, a clinically used sodium channel blocker. We also present a potential binding mode

  Hermitamides A 和 B 是从巴布亚新几内亚海洋蓝藻Lyngbya majuscula 的集合中分离出来的脂肽。我们假设 Hermitamides 是人类电压门控钠通道 (hNa V ) 的配体，这是基于它们与牙买加酰胺的结构相似性。在此，我们描述了hermitamides A 和B 及其差向异构体的非外消旋全合成。我们报告了 Hermitamides比苯妥英（一种临床使用的钠通道阻滞剂）更有效地置换 10 μM 的[ 3 H]-BTX的能力。我们还在BTX 结合位点和电生理学中展示了 ( S )-hermitamide B的潜在结合模式，表明这些化合物是 hNav1.2 电压门控钠通道的有效阻滞剂。